OncoMatch/Clinical Trials/NCT04085887
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
Is NCT04085887 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Panitumumab-IRDye800 and Pinpoint-IR9000 endoscopic/handheld device for brain tumor.
Treatment: Panitumumab-IRDye800 · Pinpoint-IR9000 endoscopic/handheld device · Explorer Air camera · PDE-NEO-II — The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Prior therapy
Cannot have received: investigational drug
Received an investigational drug within 30 days prior to first dose of Panitumumab IRDye800
Lab requirements
Blood counts
Magnesium, potassium and calcium < the lower limit of normal per institution normal lab values [excluded]
Kidney function
Serum creatinine > 1.5 times upper reference range [excluded]
Cardiac function
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); unstable angina within 6 months prior to enrollment; Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in children 1-8 years or 8-18 year old males or greater than 460 ms in infants up to 1 year or 8-18 year old females); Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in children 1 8 years or 8 to 18 year old males or greater than 460 ms in infants up to 1 year or 8 to 18 year old females) Magnesium, potassium and calcium < the lower limit of normal per institution normal lab values Serum creatinine > 1.5 times upper reference range Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Center · Stanford, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04085887 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages